PureTech Health plc (PRTC.L) LSE

134.00

-0.8(-0.59%)

Updated at October 21 12:21PM

Currency In GBp

PureTech Health plc

Address

6 Tide Street

Boston, MA 02210

United States of America

Phone

617 482 2333

Sector

Healthcare

Industry

Biotechnology

Employees

80

First IPO Date

June 19, 2015

Key Executives

NameTitlePayYear Born
Dr. Bharatt M. Chowrira J.D., Ph.D.Chief Executive Officer & Executive Director1.02M1965
Dr. Robert S. Langer Jr., Ph.D., ScDCo-Founder & Non-Executive Director202,1111949
Ms. Daphne ZoharFounder, Senior Advisor & Board Observer463,0811971
Dr. Eric Elenko Ph.D.Co-Founder & President01973
Ms. Lauren A. White M.B.A.Chief Financial Officer01979
Mr. Spencer BallExecutive Vice President of Human Resources0N/A
Dr. David R. Elmaleh Ph.D.Co-Founder & Senior Advisor01948
Mr. Michael Inbar CPA, M.B.A.Chief Accounting Officer0N/A
Ms. Allison Mead TalbotSenior Vice President of Communications & Head of Investor Relations0N/A
Mr. Charles Sherwood III, J.D., Ph.D.General Counsel & Company Secretary0N/A

Description

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.